HER2+ Breast Cancer

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

The FDA has extended its decision deadline by 3 months on a biologics license application for MYL-1401O, a trastuzumab biosimilar co-developed by Mylan and Biocon. A final decision is expected on or before December 3, 2017.

The investigational HER2-targeting antibody-drug conjugate DS-8201 has received an FDA breakthrough therapy designation for the treatment of patients with HER2-positive, locally advanced, or metastatic breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

The European Commission has approved the CDK 4/6 inhibitor ribociclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative locally advanced or metastatic breast cancer.

William J. Gradishar, MD, discusses the latest developments in the HER2-positive setting, as well as biomarker development and the potential for immunotherapy in breast cancer.

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

Gunter von Minckwitz, MD, PhD, discusses the APHINITY results and their implication for the use of pertuzumab in patients with HER2-positive breast cancer.

Twelve weeks of neoadjuvant T-DM1 with or without endocrine therapy induced superior pathologic complete response compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.

The introduction of targeted therapies has transformed HER2-positive breast cancer from an aggressive disease with poor outcomes to a highly manageable disease with potential for long-term survival.